 Verve Therapeutics Inc NASDAQ: VERV has reported new preclinical data from 36 non-human primates NHPs with its lead candidate, VERVE-101. VERVE-101 is a potential single-course gene-editing treatment for atherosclerotic cardiovascular disease ASCVD. 